16 ACTIONS IDENTIFIED FOR IMPLEMENTATION IN 2017-2020
The European Medicines Agency (EMA) has published today an action plan for small and medium-sized enterprises (SMEs), which aims to foster innovation and support SMEs in the development of novel human and veterinary medicines.
SMEs are the backbone of Europe’s economy, representing:
- The 99% of all businesses in the European Union (EU)
- SMEs are providing 2/3 of total private sector employment
- SMEs are a motor of innovation and play a major role in the development of new medicines.
To support SMEs throughout all stages of medicine development, EMA’s SME Office provides active regulatory, financial and administrative support to registered SMEs. More than 1,700 companies are currently registered with the Agency operating in the human and veterinary fields.
The plan covers four key areas and lists a series of new and enhanced actions:
1. Awareness of EMA’s SME initiative
2. Training and education
3. Support the development of innovative medicines
4. Engagement with SMEs, EU partners and stakeholders
EMA has also published today its SME office 2016 annual report providing an overview of SME-related activities in 2016 and highlights incentives and platforms that SMEs can leverage to advance innovative developments and regulatory strategies.
Please if you want to consult the original documents just click on the links below:
Framework for collaboration with academia
Europe’s next leaders: the Start-up and Scale-up Initiative
10th Anniversary of the SME initiative
